Zobrazeno 1 - 10
of 17
pro vyhledávání: '"adverse effects [Antiparkinson Agents]"'
Autor:
Devos, David, Labreuche, Julien, Dušek, Petr, Post, Bart, Bloem, Bastiaan R, Berg, Daniela, Maetzler, Walter, Otto, Markus, Habert, Marie-Odile, Lehericy, Stéphane, Ferreira, Joaquim, Dodel, Richard, Rascol, Olivier, Tranchant, Christine, Eusebio, Alexandre, Thobois, Stéphane, Marques, Ana-Raquel, Meissner, Wassilios G, Ory-Magne, Fabienne, Walter, Uwe, de Bie, Rob M A, Gago, Miguel, Vilas, Dolores, Corvol, Jean-Christophe, Kulisevsky, Jaime, Januario, Cristina, Coelho, Miguel V S, Behnke, Stefanie, Worth, Paul, Seppi, Klaus, Ouk, Thavarak, Potey, Camille, Leclercq, Céline, Viard, Romain, Duhamel, Alain, Kuchcinski, Gregory, Lopes, Renaud, Pruvo, Jean-Pierre, Pigny, Pascal, Garçon, Guillaume, Simonin, Ophélie, Carpentier, Jessica, Rolland, Anne-Sophie, Nyholm, Dag, Scherfler, Christoph, Guyon Delannoy, Pauline, Mangin, Jean-François, Chupin, Marie, Bordet, Régis, Dexter, David T, Fradette, Caroline, Spino, Michael, Tricta, Fernando, Ayton, Scott, Bush, Ashley I, Devedjian, Jean-Christophe, Poewe, Werner, Duce, James A, Cabantchik, Ioav, Defebvre, Luc, Deplanque, Dominique, Moreau, Caroline, Group, FAIRPARK-II Study, Compta, Yaroslau, Pavese, Nicola, Růžička, Evžen
Publikováno v:
The New England journal of medicine 387(22), 2045-2055 (2022). doi:10.1056/NEJMoa2209254
The New England Journal of Medicine, 387, 2045-2055
The New England Journal of Medicine, 387, 22, pp. 2045-2055
New England journal of medicine, 387(22), 2045-2055. Massachussetts Medical Society
The New England Journal of Medicine, 387, 2045-2055
The New England Journal of Medicine, 387, 22, pp. 2045-2055
New England journal of medicine, 387(22), 2045-2055. Massachussetts Medical Society
Contains fulltext : 287484.pdf (Publisher’s version ) (Open Access) BACKGROUND: Iron content is increased in the substantia nigra of persons with Parkinson's disease and may contribute to the pathophysiology of the disorder. Early research suggests
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b3511431d06e2ec946902f62c2163ae
https://doi.org/10.1056/nejmoa2209254
https://doi.org/10.1056/nejmoa2209254
Levodopa-Induced Dyskinesia Are Mediated by Cortical Gamma Oscillations in Experimental Parkinsonism
Autor:
Christoph van Riesen, Christopher Güttler, Saskia Böckmann, Andrea A. Kühn, Jennifer Altschüler, Vadim V. Nikulin, Jens K. Haumesser, Kaloyan S. Tanev
Publikováno v:
Movement disorders 36(4), 927-937 (2021). doi:10.1002/mds.28403
Movement Disorders
Movement Disorders
Background Levodopa is the most efficacious drug in the symptomatic therapy of motor symptoms in Parkinson's disease (PD); however, long‐term treatment is often complicated by troublesome levodopa‐induced dyskinesia (LID). Recent evidence suggest
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b834a43345ce1ca81ee64417bfc6ed50
https://pub.dzne.de/record/154332
https://pub.dzne.de/record/154332
Publikováno v:
Drugs & aging 36(6), 511-530 (2019). doi:10.1007/s40266-019-00654-z
Parkinson's disease is a chronic neurodegenerative movement disorder affecting people mainly beyond their 50s. Geriatric patients with Parkinson's disease experience a specific profile of comorbidities. Multimorbidity and resulting polypharmacotherap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8bb477b73227af4e42672d3bcb127334
https://pubmed.ncbi.nlm.nih.gov/30937878
https://pubmed.ncbi.nlm.nih.gov/30937878
Autor:
Wei-Hua Chiu, Thomas Carlsson, Eberhard Weihe, Martin Klietz, Günter U. Höglinger, Candan Depboylu, Ursula Keber, Martin K.-H. Schäfer
Publikováno v:
Neuroscience 331, 120-133 (2016). doi:10.1016/j.neuroscience.2016.06.017
l-3,4-Dihydroxyphenylalanine (l-DOPA) is the therapeutic gold standard in Parkinson's disease. However, most patients develop debilitating abnormal involuntary movements termed l-DOPA-induced dyskinesia (LID) as therapy-complicating side effects. The
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0246f1945a8c32bf971921001502ab7a
https://doi.org/10.1016/j.neuroscience.2016.06.017
https://doi.org/10.1016/j.neuroscience.2016.06.017
Autor:
Paul, Lingor, Joseph, Claßen, Heinz, Herbst, Alexander, Storch, Peter, Urban, Ingmar, Wellach, Wolfgang H, Jost
Publikováno v:
Fortschritte der Neurologie, Psychiatrie 86(S 01), S59-S62 (2018). doi:10.1055/a-0583-8460
Patients with Parkinson's disease show a wide heterogeneity of symptoms and comorbidities, requiring individualized therapeutic strategies, particularly in advanced stages of the disease. This is reflected by the choice of different substance classes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::45d13678d13ae0eb5dc44ee35fb5d826
https://pub.dzne.de/record/140222
https://pub.dzne.de/record/140222
Autor:
Martin K.-H. Schäfer, Eberhard Weihe, Ursula Keber, Günter U. Höglinger, Martin Klietz, Thomas Carlsson, Wolfgang H. Oertel, Candan Depboylu
Publikováno v:
Neuroscience 298, 302-317 (2015). doi:10.1016/j.neuroscience.2015.04.021
L-3,4-Dihydroxyphenylalanine (L-DOPA) is the therapeutic gold standard in Parkinson's disease. However, long-term treatment is complicated by the induction of debilitating abnormal involuntary movements termed L-DOPA-induced dyskinesias (LIDs). Until
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20049f1540beb207c7ba722153abfbc0
https://doi.org/10.1016/j.neuroscience.2015.04.021
https://doi.org/10.1016/j.neuroscience.2015.04.021
Autor:
Saskia Müller-Rebstein, Günter U. Höglinger, Carsten Culmsee, Claudia Trenkwalder, Jens Ebentheuer, Wolfgang H. Oertel
Publikováno v:
CNS drugs 31(12), 1093-1102 (2017). doi:10.1007/s40263-017-0478-0
Polypharmacy is common in geriatric Parkinson’s disease (PD) patients in advanced disease stages with multiple comorbidities, bearing multiple risks for drug safety in theory. The aim of this study was to empirically identify the most frequent and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dba533ea739db52ad07e0e160a26e83d
https://pubmed.ncbi.nlm.nih.gov/29139041
https://pubmed.ncbi.nlm.nih.gov/29139041
Publikováno v:
Der Nervenarzt 88(8), 888-894 (2017). doi:10.1007/s00115-017-0345-8
This overview focuses on the aspects of the pharmacotherapy of Parkinson's disease, which is one of the most common disorders of the nervous system. This article presents the complexity of the pharmacotherapy of geriatric patients with neurological d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::7f832ac6b2d1b868a17aabfca5e12540
Continuous leg dyskinesia assessment in Parkinson's disease -clinical validity and ecological effect
Autor:
J. Artur Serrano, Svenja Hucker, Holm Graessner, Yiannos Manoli, Ulrike Braatz, Walter Maetzler, Daniela Berg, Joaquim J. Ferreira, Janet M.T. van Uem, Tanja Heger, Robert Ramsperger, Markus A. Hobert, Stefan Meckler
Publikováno v:
Parkinsonism & related disorders 26, 41-46 (2016). doi:10.1016/j.parkreldis.2016.02.007
Dyskinesias in Parkinson's disease (PD) patients are a common side effect of long-term dopaminergic therapy and are associated with motor dysfunctions, including gait and balance deficits. Although promising compounds have been developed to treat the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b2024507411c330ef649712f0d28d315
https://pub.dzne.de/record/138585
https://pub.dzne.de/record/138585
A Placebo-Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa-Induced Dyskinesia
Autor:
Claudia, Trenkwalder, Daniela, Berg, Olivier, Rascol, Karla, Eggert, Andres, Ceballos-Baumann, Jean-Christophe, Corvol, Alexander, Storch, Lin, Zhang, Jean-Philippe, Azulay, Emmanuel, Broussolle, Luc, Defebvre, Christian, Geny, Michal, Gostkowski, Fabrizio, Stocchi, Christine, Tranchant, Pascal, Derkinderen, Franck, Durif, Alberto J, Espay, Andrew, Feigin, Jean-Luc, Houeto, Johannes, Schwarz, Thérèse, Di Paolo, Dominik, Feuerbach, Hans-Ulrich, Hockey, Judith, Jaeger, Annamaria, Jakab, Donald, Johns, Gurutz, Linazasoro, Paul, Maruff, Izabela, Rozenberg, Judit, Sovago, Markus, Weiss, Baltazar, Gomez-Mancilla
Publikováno v:
Movement disorders 31(7), 1049-1054 (2016). doi:10.1002/mds.26569
This phase 2 randomized, double-blind, placebo-controlled study evaluated the efficacy and safety of the nicotinic acetylcholine receptor α7 agonist AQW051 in patients with Parkinson's disease and levodopa-induced dyskinesia.Patients with idiopathic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::87d8f8277e4711a4fd7b611116e0b789
https://pub.dzne.de/record/138662
https://pub.dzne.de/record/138662